Education
About Us
Working with TipRanks
Follow Us
Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
GUTS Stock Chart & Stats
$1.57
-$0.12(-5.94%)
At close: 4:00 PM EST
$1.57
-$0.12(-5.94%)
Day’s Range― - ―
52-Week Range$0.83 - $3.03
Previous Close$1.96
Volume269.01K
Average Volume (3M)1.78M
Market Cap
$191.86M
Enterprise Value$87.33M
Total Cash (Recent Filing)$77.66M
Total Debt (Recent Filing)$62.18M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Apr 06, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding137,044,430
10 Day Avg. Volume2,526,420
30 Day Avg. Volume1,776,972
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.16
Price to Sales (P/S)964.47
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue29.11K
Enterprise Value/Gross Profit-304.27
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$7.75Price Target Upside393.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessFractyl announced positive midpoint randomized cohort results from the ongoing pivotal REMAIN-1 clinical trial evaluating Revita DMR procedure for weight loss/maintenance after GLP-1 RA discontinuation.
Financial HealthFractyl ended with $77.7 million in cash, expected to fund operations into early 2027, indicating strong financial health.
Product EfficacyThe Revita Duodenal Mucosal Resurfacing System and the preclinical RJVA-001 pancreatic gene therapy have shown sustained weight loss and glucose control efficacy with favorable safety and tolerability.
Bears Say
Current Market ChallengesCurrent GLP-1 therapies have high discontinuation rates and the risk of metabolic rebound after withdrawal, as well as significant gastrointestinal side effects.
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $0.82 and its highest was $3.03 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $191.86M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 125 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.316 by -$0.394.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.18.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 137,044,430 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.316. Following the earnings report the stock price went down -0.885%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
Fractyl Health, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.75 (393.63% Upside)
$7.75 (393.63% Upside)
Hedge Fund Trend
Increased
By 4.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.9%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.14%
12-Months-Change
Fundamentals
Return on Equity
-518.40%
Trailing 12-Months
Asset Growth
-9.97%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc. (GUTS) is a biotechnology company focused on transforming the treatment landscape for metabolic diseases, particularly type 2 diabetes and obesity. The company operates in the healthcare sector and is recognized for its innovative approach to metabolic health, leveraging advanced technologies to develop therapies that target the underlying causes of these conditions. Fractyl's core product is the Revita procedure, a minimally invasive endoscopic technique designed to improve metabolic function and promote weight loss through the modulation of gut hormones.
GUTS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Fractyl Health, Inc. is experiencing significant clinical and financial progress, particularly with the Revita procedure's promising results in sustaining weight loss post-GLP-1 therapy and robust financial positioning. However, the increased net loss and weight regain in the sham group highlight some challenges.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$7.75
▲(393.63% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Genfit SA
―
Innate Pharma
―
Ownership Overview
16.37% Insiders
1.45% Mutual Funds
53.57% Other Institutional Investors
27.29% Public Companies and Individual Investors
Options Prices
Currently, No data available
---